In December 2022, Asymchem’s Boston site was established to provide direct service to biotech clients with a focus on providing a full range of operations and services for the company’s global partners. The site’s focus on small molecules, oligonucleotides, and peptides is only a small piece of their entire work scope.
The site is fully equipped and capable of carrying projects through early-stage phase development and beyond, including API process development, preliminary pre-formulation, solid characterization, and research and development efforts for both drug substances and drug products. The various labs led by Asymchem’s dedicated scientists are a focal point in enhancing clients’ CMC experience to make it more seamless and diversified.
As an extension of Asymchem’s China-based manufacturing, the Boston site is a necessary addition that assists in scaling projects in a more efficient timeframe without compromising the quality. As a one-stop shop for CDMO services, Boston’s site rounds out Asymchem’s internal ecosystem to support not only rising biotech companies but also more established ones that seek a fully integrated CMC experience.